# Immunotherapy With N 803, ETBX-071, and M-CENK in Combination With Radiation for Participants With High-Risk Prostate Cancer.

> **NCT06765954** · PHASE2 · WITHDRAWN · sponsor: **ImmunityBio, Inc.**

## Conditions studied

- High-risk Prostate Cancer

## Interventions

- **DRUG:** N-803 (IL-15 Superagonist)
- **DRUG:** ETBX-071 (PSA-based Oncolytic Virus)
- **DRUG:** M-CENK (Activated NK Cells)
- **RADIATION:** External Beam Radiation Therapy (EBRT)
- **RADIATION:** Androgen Deprivation Therapy (ADT)
- **RADIATION:** Post-radiation immunotherapy

## Key facts

- **NCT ID:** NCT06765954
- **Lead sponsor:** ImmunityBio, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2025-12-01
- **Primary completion:** 2031-01-31
- **Final completion:** 2031-06-30
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Study was redeveloped into a new protocol
- **Last updated:** 2026-05-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06765954

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06765954, "Immunotherapy With N 803, ETBX-071, and M-CENK in Combination With Radiation for Participants With High-Risk Prostate Cancer.". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06765954. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*